Stanford researchers have discovered the first of its kind gene therapy vector to treat eye diseases of the non-pigmented ciliary epithelium cells (NPCECs).
Stanford researchers have applied large-scale proteomic platforms to identify biomarkers that can be used to diagnose uveal melanoma and subtype eye tumors according to their gene expression profile (GEP) class or PRAME status.
Stanford researchers have discovered that dietary metabolites, specifically alpha-ketoglutarate, are able to delay retinal degeneration to treat blinding retinal diseases regardless of the type of retinal condition.